NeuroThera Labs Accelerates Autism Trial Enrollment with 26 of 60 Patients
Event summary
- NeuroThera Labs, a SciSparc subsidiary, has enrolled 26 of 60 planned patients in its SCI-210 autism trial.
- The double-blind, placebo-controlled study evaluates a CBD and CannAmide™ combination for autism symptom relief.
- Trial conducted at Soroka Medical Center in Israel, designed with National Autism Research Center.
- Primary endpoints include ABC-C parent questionnaire and CGI-I clinician assessment.
The big picture
NeuroThera's rapid enrollment in the SCI-210 trial reflects growing clinical interest in cannabinoid combinations for neurodevelopmental disorders. The study's design, incorporating both parent and clinician assessments, positions it as a potential differentiator in autism treatment research. Success could validate NeuroThera's approach to dual-compound therapies, potentially opening new markets beyond Israel.
What we're watching
- Trial Completion Pace
- Whether NeuroThera can maintain current enrollment momentum to reach 60 patients.
- Therapeutic Efficacy
- How the CBD-CannAmide™ combination performs against CBD monotherapy in autism symptom relief.
- Regulatory Pathway
- The timeline for potential Israeli approval and subsequent international expansion.